The Future of Airway Disorders: Precision Medicine Takes Center Stage
The 90th anniversary of the global pulmonary conference, CHEST 2025, marked a pivotal moment in the evolution of asthma and COPD treatment. But here's where it gets controversial—is precision medicine truly the future, or are we overlooking the patient's voice?
Dr. Nicola A. Hanania, MD, MS, shared insights from the conference, emphasizing the shift towards tailored care. In asthma, the focus is on biologics, with clinicians grappling with questions of timing, selection, and patient suitability. With six approved biologics, real-world data is making it harder to pinpoint the right choice. The use of biomarkers, patient characteristics, and comorbidities is becoming crucial in this decision-making process.
Remission in asthma is a hot topic, but what does it mean? Hanania discussed the potential for reducing controller therapy in patients achieving remission on biologics, but questions remain. What constitutes clinical remission? Can we taper biologics? These uncertainties highlight the need for further research and a universal definition.
COPD care is making strides, with approved biologics for specific patient groups. Studies like MATINEE show the potential for reduced oral steroid use with biologics. Patient-reported outcomes are gaining importance, as seen with dupilumab's impact on symptoms and exacerbations. Novel agents like ensifentrine improve lung function and symptoms, even in patients without exacerbations.
The role of biomarkers is evolving, but is it enough? Blood eosinophil counts are valuable in asthma and COPD, predicting exacerbations and treatment response. Composite biomarkers, like FeNO, show promise when combined with blood eosinophils. CT imaging biomarkers are emerging but require further study. The challenge is to balance biomarker-driven decisions with patient-reported outcomes and expectations.
Hanania emphasizes the importance of shared decision-making, considering patient priorities and preferences. The choice of inhaler and patient adherence are critical factors. The focus on small airway function and disease highlights a shift in clinical thinking, moving beyond traditional measures like FEV1.
CHEST 2025 showcased a paradigm shift in airway disorder management, embracing precision medicine and patient-centric care. As we approach CHEST's 100th anniversary, the next decade promises even more tailored and effective treatments. But the question remains: how do we ensure that precision medicine doesn't overshadow the patient's voice in this rapidly evolving landscape?
